Access content directly

Gwenaelle Gravis

Current affiliations
  • 179570
Researcher identifiers


MD, Head of Onco-Urology Unit, Institut Paoli Calmettes and Aix-Marseille University


A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol study

Gwenaelle Gravis , Patricia Marino , Daniel Olive , Frederique Penault-Llorca , Jean-Pierre Delord
BMC Cancer, 2023, 23 (1), pp.393. ⟨10.1186/s12885-023-10881-8⟩
Journal articles hal-04109560v1
Image document

Real-World Treatment Patterns Among French Patients With Metastatic Castration-Resistant Prostate Cancer Under Abiraterone or Enzalutamide

Lucie-Marie Scailteux , Sebastien Vincendeau , Gwenaelle Gravis , Romain Mathieu , Frederic Balusson
Clinical Genitourinary Cancer, 2023, ⟨10.1016/j.clgc.2023.04.004⟩
Journal articles hal-04121016v1
Image document

Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial

Stéphane Culine , Valentin Harter , Clémentine Krucker , Gwénaëlle Gravis , Aude Fléchon
Cancers, 2023, 15 (6), pp.1742. ⟨10.3390/cancers15061742⟩
Journal articles hal-04195179v1

Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial

Yann-Alexandre Vano , Réza Elaidi , Mostefa Bennamoun , Christine Chevreau , Delphine Borchiellini
Lancet Oncology, 2022, 23 (5), pp.612-624. ⟨10.1016/S1470-2045(22)00128-0⟩
Journal articles hal-04072026v1

Self-reported functional assessment after treatment for prostate cancer: 5-year results of the prospective cohort VICAN

Géraldine Pignot , Rajae Touzani , Marc-Karim Bendiane , Julien Mancini , Jochen Walz
Future Oncology, 2022, 18 (14), pp.1733-1744. ⟨10.2217/fon-2021-1420⟩
Journal articles inserm-04039329v1
Image document

The Psychological Distress of Cancer Patients following the COVID-19 Pandemic First Lockdown: Results from a Large French Survey

Patricia Marino , Rajae Touzani , Jihane Pakradouni , Patrick Ben Soussan , Gwenaelle Gravis
Cancers, 2022, 14 (7), pp.1794. ⟨10.3390/cancers14071794⟩
Journal articles inserm-04042655v1
Image document

Impact of active surveillance for prostate cancer on the risk of depression and anxiety

Davidson Sypre , Géraldine Pignot , Rajae Touzani , Patricia Marino , Jochen Walz
Scientific Reports, 2022, 12 (1), pp.12889. ⟨10.1038/s41598-022-17224-w⟩
Journal articles inserm-04048149v1

Molecular Profiles of Advanced Urological Cancers in the PERMED-01 Precision Medicine Clinical Trial

Émilien Billon , Gwenaelle Gravis , Arnaud Guille , Nadine Carbuccia , José Adélaïde
Cancers, 2022, 14 (9), ⟨10.3390/cancers14092275⟩
Journal articles hal-04085310v1

Cabozantinib-nivolumab sequence in metastatic renal cell carcinoma: The CABIR study

Yann-Alexandre Vano , Letuan Phan , Gwenaelle Gravis , Iphigenie Korakis , Friederike Schlurmann
International Journal of Cancer, 2022, 151 (8), pp.1335-1344. ⟨10.1002/ijc.34126⟩
Journal articles hal-04084994v1
Image document

Cabozantinib-nivolumab sequence in metastatic renal cell carcinoma: The CABIR study

Yann‐alexandre Vano , Letuan Phan , Gwenaelle Gravis , Iphigénie Korakis , Friederike Schlürmann
International Journal of Cancer, 2022, 151 (8), pp.1335-1344. ⟨10.1002/ijc.34126⟩
Journal articles hal-04085018v1
Image document

A non-inferiority randomized phase III trial of standard immunotherapy versusreduced dose intensity in responding patients with metastatic cancer: MOIO study.

Gwenaelle Gravis , Daniel Olive , Patricia Marino , Frederique Madeleine Penault-Llorca , Jean-Pierre Delord
Journal of Clinical Oncology, 2022, 40 (16_suppl), pp.TPS2674. ⟨10.1200/JCO.2022.40.16_suppl.TPS2674⟩
Journal articles hal-03929783v1

Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma

Lucie Meynard , Derek Dinart , Blandine Delaunay , Aude Flechon , Carolina Saldana
European Journal of Cancer, 2022, 175, pp.43-53. ⟨10.1016/j.ejca.2022.08.014⟩
Journal articles hal-03836416v1

Escherichia coli –Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer

Anne-Gaëlle Goubet , Leonardo Lordello , Carolina Alves Costa Silva , Isabelle Peguillet , Marianne Gazzano
Cancer Discovery, 2022, 12 (10), pp.2280-2307. ⟨10.1158/2159-8290.CD-22-0201⟩
Journal articles hal-03951702v1

Should Prostate Cancer Patients With History of Cardiovascular Events Be Preferentially Treated With Luteinizing Hormone-Releasing Hormone Antagonists?

Steven Tisseverasinghe , Marwan Tolba , Fred Saad , Gwenaelle Gravis , Boris Bahoric
Journal of Clinical Oncology, 2022, 40 (36), pp.4173+. ⟨10.1200/JCO.22.00883⟩
Journal articles hal-04084956v1
Image document

1642P Improve the conditions of lockdown may decrease anxiety among cancer patients during the COVID-19 pandemic

G. Gravis Mescam , R. Touzani , J. Pakradouni , P. Bens Soussan , P. Marino
Annals of Oncology, 2021, 32, pp.S1160. ⟨10.1016/j.annonc.2021.08.1635⟩
Journal articles inserm-03667002v1

665P Role of prior nephrectomy for synchronous metastatic renal cell carcinoma (mRCC) on efficacy in patients treated with avelumab + axitinib (A + Ax) or sunitinib (S): Results from JAVELIN Renal 101

M-O. Grimm , M. Oya , T.K. Choueiri , M. Schmidinger , D.I. Quinn
Annals of Oncology, 2021, 32, pp.S690-S691. ⟨10.1016/j.annonc.2021.08.061⟩
Journal articles hal-03623392v1

Multicentric phase II trial of TI‐CE high‐dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors

Christine Chevreau , Christophe Massard , Aude Flechon , Rémy Delva , Gwenaëlle Gravis
Cancer Medicine, 2021, 10 (7), pp.2250-2258. ⟨10.1002/cam4.3687⟩
Journal articles hal-03208728v1

Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy?

Arnaud Méjean , Alain Ravaud , Simon Thezenas , Christine Chevreau , Karim Bensalah
European Urology, 2021, 80 (4), pp.417-424. ⟨10.1016/j.eururo.2021.06.009⟩
Journal articles hal-03345230v1

Feasibility and first results of digital patient-reported outcomes measures (PROMs) data collection for patients with localized prostate cancer at diagnosis.

Geraldine Pignot , Marion Picini , Patricia Marino , Naji Salem , Stanislas Rybikowski
Journal of Clinical Oncology, 2021, 39 (15_suppl), pp.12071-12071. ⟨10.1200/JCO.2021.39.15_suppl.12071⟩
Journal articles hal-03623123v1
Image document

Prognostic Risk Classification for Biochemical Relapse-Free Survival in Oligometastatic Recurrent Prostate Cancer Determined by Choline PET

Gwenaelle Gravis , Aurélie Autret , Morgane Guibert-Broudic , Thomas Dubergé , Christophe Zemmour
Clinical Genitourinary Cancer, 2021, 19 (4), pp.346-353. ⟨10.1016/j.clgc.2021.03.004⟩
Journal articles hal-03623562v1

Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial

T.K. Choueiri , J. Larkin , S. Pal , R.J. Motzer , B.I. Rini
ESMO Open, 2021, 6 (3), pp.100101. ⟨10.1016/j.esmoop.2021.100101⟩
Journal articles hal-03623572v1
Image document

Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study

Stéphane Culine , Aude Fléchon , Gwenaelle Gravis , Guilhem Roubaud , Yohann Loriot
Clinical Genitourinary Cancer, 2021, 19 (4), pp.e216-e222. ⟨10.1016/j.clgc.2021.02.005⟩
Journal articles hal-03631553v1

Cost-effectiveness Analysis of Innovative Therapy for Patients with Newly Diagnosed Hormone-Sensitive Metastatic Prostate Cancer

Rémi Pelloux-Prayer , Philomène Schiele , Stéphane Oudard , Gwenaëlle Gravis , François Kleinclauss
Clinical Genitourinary Cancer, 2021, 19 (5), pp.e326-e333. ⟨10.1016/j.clgc.2021.03.022⟩
Journal articles hal-03612906v1

Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial

Stéphane Culine , Valentin Harter , Gwenaelle Gravis , Aude Fléchon , Christine Chevreau
Clinical Genitourinary Cancer, 2021, 19 (6), pp.554-562. ⟨10.1016/j.clgc.2021.08.005⟩
Journal articles hal-03625944v1

Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial

François Bertucci , Anthony Gonçalves , Arnaud Guille , José Adelaïde , Séverine Garnier
Genome Medicine, 2021, 13 (1), pp.87. ⟨10.1186/s13073-021-00897-9⟩
Journal articles hal-03583277v1
Image document

Advance Approval of Outpatient Chemotherapy via Phone Call Optimizes Healthcare Delivery without Compromising Patient Satisfaction with Care

Patricia Marino , Rajae Touzani , Lorène Seguin , Jean Francois Moulin , Myriam Palomares
Cancers, 2021, 13 (6), pp.1337. ⟨10.3390/cancers13061337⟩
Journal articles inserm-03462202v1

Gastrointestinal Metastases From Primary Renal Cell Cancer: A Single Center Review

Maelle Rony , Jean-Philippe Ratone , Jochen Walz , Geraldine Pignot , Fabrice Caillol
Frontiers in Oncology, 2021, 11, ⟨10.3389/fonc.2021.644301⟩
Journal articles hal-03623317v1

Impact of active surveillance for prostate cancer on the risk of depression and anxiety: Patient-reported outcomes (PROs) from the Vican Prospective Cohort.

Geraldine Pignot , Rajae Touzani , Patricia Marino , Jochen Walz , Stanislas Rybikowski
Journal of Clinical Oncology, 2021, 39 (6SUPPL), pp.220-220. ⟨10.1200/JCO.2021.39.6_suppl.220⟩
Journal articles inserm-03665171v1

Phase 2 study of retifanlimab (INCMGA00012) in patients (pts) with selected solid tumors (POD1UM-203).

Michele Maio , Michael Schenker , Jacques Medioni , Slawomir Mandziuk , Margarita Majem
Journal of Clinical Oncology, 2021, 39 (15_suppl), pp.2571-2571. ⟨10.1200/JCO.2021.39.15_suppl.2571⟩
Journal articles hal-03623326v1
Image document

Endoscopic Ultrasound-Guided Radiofrequency Ablation as an Future Alternative to Pancreatectomy for Pancreatic Metastases from Renal Cell Carcinoma: A Prospective Study

Brice Chanez , Fabrice Caillol , Jean-Philippe Ratone , Christian Pesenti , Philippe Rochigneux
Cancers, 2021, 13 (21), pp.5267. ⟨10.3390/cancers13215267⟩
Journal articles hal-03689914v1

Soluble BTN2A1 Is a Potential Prognosis Biomarker in Pre-Treated Advanced Renal Cell Carcinoma

Emilien Billon , Brice Chanez , Philippe Rochigneux , Laurence Albiges , Cécile Vicier
Frontiers in Immunology, 2021, 12, ⟨10.3389/fimmu.2021.670827⟩
Journal articles hal-03623028v1

Corrigendum: Gastrointestinal Metastases From Primary Renal Cell Cancer: A Single Center Review

Maelle Rony , Jean-Philippe Ratone , Jochen Walz , Geraldine Pignot , Fabrice Caillol
Frontiers in Oncology, 2021, 11, ⟨10.3389/fonc.2021.710477⟩
Journal articles hal-03623373v1

Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d'Etude des Tumeurs Uro-Genitales)

Mathilde Cancel , Gaelle Fromont , Cyriac Blonz , Christine Chevreau , Nathalie Rioux-Leclercq
European Journal of Cancer, 2021, 158, pp.1-11. ⟨10.1016/j.ejca.2021.08.046⟩
Journal articles hal-03476711v1
Image document

L’annonce du cancer au diagnostic de Tumeur de vessie non infiltrant le muscle modifie-t-elle la qualité de vie et l’observance des patients ? Données de la cohorte prospective française VICAN

J Campagna , R Touzani , G Gravis , P Marino , J Walz
Progrès en Urologie, 2021, S1166-7087 (21), pp.00213-X. ⟨10.1016/j.purol.2021.08.035⟩
Journal articles inserm-03462183v1

Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial

Bernadett Szabados , Alejo Rodriguez-Vida , Ignacio Durán , Simon Crabb , Michiel van Der Heijden
European Urology Oncology, 2021, 4 (3), pp.456-463. ⟨10.1016/j.euo.2020.11.010⟩
Journal articles hal-03623603v1

Erratum to ‘Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial’

T.K. Choueiri , J. Larkin , S. Pal , R.J. Motzer , B.I. Rini
ESMO Open, 2021, 6 (4), pp.100177. ⟨10.1016/j.esmoop.2021.100177⟩
Journal articles hal-03623494v1

Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program

Laurence Albiges , Aude Fléchon , Christine Chevreau , Delphine Topart , Gwenaëlle Gravis
European Journal of Cancer, 2021, 142, pp.102-111. ⟨10.1016/j.ejca.2020.09.030⟩
Journal articles hal-03623382v1
Image document

Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses

Christian Pfister , Gwenaelle Gravis , Aude Fléchon , Michel Soulié , Laurent Guy
European Urology, 2020, ⟨10.1016/j.eururo.2020.08.024⟩
Journal articles hal-02995530v1
Image document

Deterioration of Sexual Health in Cancer Survivors Five Years after Diagnosis: Data from the French National Prospective VICAN Survey

Lorène Seguin , Rajae Touzani , Anne-Déborah Bouhnik , Ali Ben Charif , Patricia Marino
Cancers, 2020, 12 (11), pp.3453. ⟨10.3390/cancers12113453⟩
Journal articles inserm-03192591v1
Image document

Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial

Sylvie Négrier , Nathalie Rioux-Leclercq , Céline Ferlay , Marine Gross-Goupil , Gwénaelle Gravis
European Journal of Cancer, 2020, 129, pp.107 - 116. ⟨10.1016/j.ejca.2020.02.001⟩
Journal articles hal-02552562v1

Pharmacokinetic and Pharmacogenetic Study of Etoposide in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors

Sotheara Moeung , Christine Chevreau , Sabrina Marsili , Christophe Massart , Aude Fléchon
Pharmaceutical Research, 2020, 37 (7), pp.147. ⟨10.1007/s11095-020-02861-5⟩
Journal articles hal-02935842v1

Essai GETUG/AFU-V05 VESPER phase III randomisée de chimiothérapie périopératoire (schéma MVAC dose-dense ou GC) dans le cancer de vessie infiltrant localisé. Résultats sur la toxicité de la chimiothérapie et la réponse histologique

C. Pfister , G. Gravis , A. Flechon , M. Soulie , Laurent Guy
Progrès en Urologie, 2020, 30 (13), pp.715-716. ⟨10.1016/j.purol.2020.07.038⟩
Journal articles hal-02995801v1

Estimation of Unbound Carboplatin Clearance From Total Plasma Concentrations as a Means of Facilitating Therapeutic Drug Monitoring

Sotheara Moeung , Christine Chevreau , Vianney Poinsignon , Jérôme Guitton , Bénédicte Lelièvre
Therapeutic Drug Monitoring, 2019, 41 (1), pp.66-74. ⟨10.1097/FTD.0000000000000569⟩
Journal articles hal-02481351v1

Denosumab Toxicity When Combined With Anti-angiogenic Therapies on Patients With Metastatic Renal Cell Carcinoma: A GETUG Study

Aline Guillot , Charlotte Joly , Philippe Barthélémy , Emeline Meriaux , Sylvie Négrier
Clinical Genitourinary Cancer, 2019, 17 (1), pp.e38-e43. ⟨10.1016/j.clgc.2018.08.006⟩
Journal articles hal-02420071v1

Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group

Marine Sroussi , Reza Elaidi , Aude Fléchon , Marianne Lorcet , Delphine Borchiellini
Clinical Genitourinary Cancer, 2019, ⟨10.1016/j.clgc.2019.11.014⟩
Journal articles hal-02556645v1

Adaptation and validation of the memorial anxiety scale for prostate cancer (MAX-PC) in a sample of French men

Rajae Touzani , Julien Mancini , Jaïs Troian , Anne-Déborah Bouhnik , Olivier Cussenot
Journal of patient-reported outcomes / J Patient Rep Outcomes, 2019, 3 (1), ⟨10.1186/s41687-019-0150-1⟩
Journal articles hal-02625852v1

Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study

Ronan Flippot , Cécile Dalban , Brigitte Laguerre , Delphine Borchiellini , Gwénaelle Gravis
Journal of Clinical Oncology, 2019, 37 (23), pp.2008--2016. ⟨10.1200/JCO.18.02218⟩
Journal articles hal-02931819v1

Poly (ADP-Ribose) Polymerase Inhibitors for De Novo BRCA2-Null Small-Cell Prostate Cancer

Brice Chanez , Max Chaffanet , José Adélaide , Jeanne Thomassin , Séverine Garnier
JCO precision oncology, 2018, 2, pp.1-8. ⟨10.1200/po.18.00083⟩
Journal articles hal-03623699v1

Gender difference in cancer survivors' perceived information 5-years after diagnosis: Data from the French national study - VICAN 5

G. Gravis , R. Touzani , A-D. Bouhnik , P. Marino , G. Pignot
Annals of Oncology, 2018, 29 (8)
Journal articles hal-02143650v1

Unexpected response to cisplatin rechallenge after immune checkpoint inhibitors in patients with metastatic urothelial carcinoma refractory to platinum regimen

Gwenaelle Gravis , Emilien Billon , Capucine Baldini , Christophe Massard , Werner Hilgers
European Journal of Cancer, 2018, 104, pp.236-238. ⟨10.1016/j.ejca.2018.09.002⟩
Journal articles hal-02143638v1

Long-term efficacy of crizotinib in a metastatic papillary renal carcinoma with MET amplification: a case report and literature review

Philippe Rochigneux , Jeanne Thomassin-Piana , Sophy Laibe , Serge Brunelle , Naji Salem
BMC Cancer, 2018, 18 (1), pp.1159. ⟨10.1186/s12885-018-5049-3⟩
Journal articles hal-03689938v1

Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies

Gwenaëlle Gravis , Jean-Marie Boher , Yu-Hui Chen , Glenn Liu , Karim Fizazi
European Urology, 2018, 73 (6), pp.847-855. ⟨10.1016/j.eururo.2018.02.001⟩
Journal articles inserm-02092595v1

Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer

G. V. Long , S. S. Tykodi , J. G. Schneider , C. Garbe , G. Gravis
Annals of Oncology, 2018, 29 (11), pp.2208-2213. ⟨10.1093/annonc/mdy408⟩
Journal articles hal-02143540v1

Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma

A. Mejean , A. Ravaud , S. Thezenas , S. Colas , J. -B. Beauval
New England Journal of Medicine, 2018, 379 (5), pp.417-427. ⟨10.1056/NEJMoa1803675⟩
Journal articles hal-02143533v1

Impact of Patient- and Clinician-Reported Cumulative Toxicity on Quality of Life in Patients With Metastatic Castration-Naive Prostate Cancer

Claudia S. E. W. Schuurhuizen , Patricia Marino , Annemarie M. J. Braamse , Laurien M. Buffart , Florence Joly
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2018, 16 (12), pp.1481-1488. ⟨10.6004/jnccn.2018.7069⟩
Journal articles hal-02143628v1
Image document

The role and use of Patient Reported Outcomes in the management of cancer patients

Patricia Marino , Marie Bannier , Jean-François Moulin , Gwenaëlle Gravis
Bulletin du Cancer, 2018, 105 (6), pp.603-609. ⟨10.1016/j.bulcan.2018.02.008⟩
Journal articles inserm-02096334v1

Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter Study

Sotheara Moeung , Christine Chevreau , Sophie Broutin , Jérome Guitton , Bénédicte Lelièvre
Clinical Cancer Research, 2017, 23 (23), pp.7171 - 7179. ⟨10.1158/1078-0432.CCR-17-1344⟩
Journal articles hal-01659726v1

Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial

P Lavaud , G Gravis , S Foulon , F Joly , S Oudard
European Urology, 2017, ⟨10.1016/j.eururo.2017.09.022⟩
Journal articles hal-01950269v1
Image document

Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature

Gwenaëlle Gravis , François Audenet , Jacques Irani , Marc-Olivier Timsit , Philippe Barthélémy
Cancer Treatment Reviews, 2017, 55, pp.211-217. ⟨10.1016/j.ctrv.2016.09.008⟩
Journal articles hal-01632557v1

Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor Activity

Christine Pasero , Gwenaëlle Gravis , Mathilde Guerin , Samuel Granjeaud , Jeanne Thomassin-Piana
Cancer Research, 2016, 76 (8), pp.2153-2165. ⟨10.1158/0008-5472.CAN-15-1965⟩
Journal articles hal-03599184v1
Image document

Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial

Gwenaelle Gravis , Jean-Marie Boher , Florence Joly , Michel Soulié , Laurence Albiges
European Urology, 2016, 70, pp.256 - 262. ⟨10.1016/j.eururo.2015.11.005⟩
Journal articles inserm-03343628v1

Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?

Damien Pouessel , Sylvie Chevret , Frédéric Rolland , Gwenaëlle Gravis , Lionel Geoffrois
European Journal of Cancer, 2016, 54, pp.69--74. ⟨10.1016/j.ejca.2015.11.017⟩
Journal articles hal-01278607v1

Intermediate analysis of a phase II trial assessing gemcitabine and cisplatin in locoregional or metastatic penile squamous cell carcinoma

Nadine Houédé , Laura Dupuy , Aude Fléchon , Philippe Beuzeboc , Gwenaëlle Gravis
BJU International, 2016, 117 (3), pp.444 - 449. ⟨10.1111/bju.13054⟩
Journal articles hal-01938234v1

Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial

Karim Fizazi , Laura Faivre , François Lesaunier , Remy Delva , Gwenaëlle Gravis
Lancet Oncology, 2015, 16 (7), pp.787 - 794. ⟨10.1016/S1470-2045(15)00011-X⟩
Journal articles hal-01914904v1

Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features

Romain Mathieu , Géraldine Pignot , Alexandre Ingles , Maxime Crépel , Pierre Bigot
Urologic Oncology: Seminars and Original Investigations, 2015, 33 (8), pp.339.e9-339.e15. ⟨10.1016/j.urolonc.2015.05.014⟩
Journal articles hal-01260654v1
Image document

Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model

Gwenaelle Gravis , Jean-Marie Boher , Karim Fizazi , Florence Joly , Franck Priou
European Urology, 2015, 68 (2), pp.196 - 204. ⟨10.1016/j.eururo.2014.09.022⟩
Journal articles inserm-03353959v1
Image document

Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France

Nadine Houédé , Philippe Beuzeboc , Sophie Gourgou , Diego Tosi , Laura Moise
BMC Cancer, 2015, 15 (1), pp.222. ⟨10.1186/s12885-015-1257-2⟩
Journal articles inserm-01264474v1

Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: Long term outcome of the Temporary Authorization for Use program in France.

Nadine Houede , Philippe Beuzeboc , Sophie Gourgou , Diego Tosi , Laura Moise
Journal of Clinical Oncology, 2015, 33 (7_suppl), pp.264-264. ⟨10.1200/jco.2015.33.7_suppl.264⟩
Journal articles hal-03578471v1

Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project

A. Kramar , S. Negrier , R. Sylvester , S. Joniau , P. Mulders
Annals of Oncology, 2015, 26 (12), pp.2392-8. ⟨10.1093/annonc/mdv380⟩
Journal articles hal-01913181v1

A serum metabolomic fingerprint of bevacizumab and temsirolimus combination as first-line treatment of metastatic renal cell carcinoma

Elodie Jobard , Ellen Blanc , Sylvie Négrier , Bernard Escudier , Gwenaëlle Gravis
British Journal of Cancer, 2015, 113 (8), pp.1148-1157. ⟨10.1038/bjc.2015.322⟩
Journal articles hal-01234309v1

Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial

K. Fizazi , G. Gravis , Aude Flechon , L. Geoffrois , C. Chevreau
Annals of Oncology, 2014, 25, pp.987--91. ⟨10.1093/annonc/mdu099⟩
Journal articles hal-02168058v1

Patients’ self-assessment versus investigators’ evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15).

Gwenaëlle Gravis , Patricia Marino , Florence Joly , Stéphane Oudard , Franck Priou
European Journal of Cancer, 2014, pp.953 - 962. ⟨10.1016/j.ejca.2013.11.034⟩
Journal articles hal-01917876v1

VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis

Benoit Beuselinck , Alexandra Karadimou , Diether Lambrechts , Bart Claes , Pascal Wolter
Acta Oncologica, 2014, 53 (1), pp.103--112. ⟨10.3109/0284186X.2013.770600⟩
Journal articles hal-01064635v1
Image document

FGFR1 and WT1 are markers of human prostate cancer progression.

Elizabeth Devilard , Franck Bladou , Olivier Ramuz , Gilles Karsenty , Jean-Philippe Dalès
BMC Cancer, 2006, 6, pp.272. ⟨10.1186/1471-2407-6-272⟩
Journal articles inserm-00121110v1

Quality of life of breast cancer patients receiving high-dose-intensity chemotherapy: impact of length of cycles

Dominique Genre , C. Protière , Geneviève Macquart-Moulin , G. Gravis , Jacques Camerlo
Supportive Care in Cancer, 2002, 10 (3), pp.222-230. ⟨10.1007/s00520-001-0322-3⟩
Journal articles inserm-03199677v1
Image document

Modulations of dose intensity of doxorubicin and cyclophosphamide in association with G-CSF and peripheral blood stem cells in adjuvant chemotherapy for breast cancer: comparative evaluation of completion and safety of three intensive regimens

D. Genre , P. Viens , F. Bertucci , C Chabannon , G. Gravis
Bone Marrow Transplantation, 2002, 29 (11), pp.881-886. ⟨10.1038/sj.bmt.1703556⟩
Journal articles inserm-03199676v1